Drugs / ActiveMatrix
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05844930 | Jan 2023 → Feb 2025 | frozen shoulder | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT05297513 | Jul 2022 → Jul 2025 overdue | lumbar spinal stenosis | Baylor College of Medicine | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ActiveMatrix | “1cc ActiveMatrix (Skye Biologics, Inc.)” NCT05844930 ↗ |
| Modality | Other / unclassified | “Skye Biologics offers placental tissue-based matrices in the form of both flowable and solid mediums.” NCT05297513 ↗ |
| Route | Topical | “the ActiveMatrix product will be administered on top of the dura mater and again on the closed fascia” NCT05297513 ↗ |